L. Donnelly, D. Evans, J. Wiseman, J. Fox, R. Greenhalgh et al., Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic, British Journal of Cancer, vol.1, issue.7, pp.1681-1688, 2014.
DOI : 10.1007/s10549-012-2089-2

K. Metcalfe, C. Snyder, J. Seidel, D. Hanna, H. Lynch et al., The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation, Familial Cancer, vol.10, issue.6, pp.97-103, 2005.
DOI : 10.1007/s10689-005-4215-3

J. Cuzick, I. Sestak, and B. Bonanni, Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data, The Lancet, vol.381, issue.9880, pp.1827-1861, 2013.
DOI : 10.1016/S0140-6736(13)60140-3

S. Narod, Tamoxifen chemoprevention?end of the road? Journal of the Amercican Medical Association Oncology, pp.1033-1037, 2015.

V. Moyer and U. S. , Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, vol.159, pp.698-708, 2013.

K. Visvanathan, P. Hurley, E. Bantug, P. Brown, N. Col et al., Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.31, issue.23, pp.2942-62, 2013.
DOI : 10.1200/JCO.2013.49.3122

M. Schwartz, C. Isaacs, K. Graves, E. Poggi, B. Peshkin et al., testing: risk reduction and surveillance, Cancer, vol.138, issue.2, pp.510-517, 2012.
DOI : 10.1001/archsurg.138.12.1323

R. Heisey, N. Pimlott, M. Clemons, S. Cummings, and N. Drummond, Women's views on chemoprevention of breast cancer: qualitative study, Can Fam Physician, vol.52, pp.625-332, 2006.

A. Fagerlin, B. Zikmund-fisher, D. Smith, V. Nair, H. Derry et al., Women???s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid, Breast Cancer Research and Treatment, vol.319, issue.7212, pp.613-633, 2010.
DOI : 10.1136/bmj.319.7212.731

E. Razzaboni, A. Toss, L. Cortesi, I. Marchi, F. Sebastiani et al., Acceptability and Adherence in a Chemoprevention Trial among Women at Increased Risk for Breast Cancer Attending the Modena Familial Breast and Ovarian Cancer Center (Italy), The Breast Journal, vol.3, issue.1, pp.10-21, 2013.
DOI : 10.1158/1940-6207.CAPR-10-0096

L. Fallowfield, A. Fleissig, R. Edwards, A. West, T. Powles et al., Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials, Journal of Clinical Oncology, vol.19, issue.7, pp.1885-92, 2001.
DOI : 10.1200/JCO.2001.19.7.1885

J. Melnikow, D. Paterniti, R. Azari, C. Kuenneth, S. Birch et al., Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction, Cancer, vol.85, issue.10, pp.1996-2005, 2005.
DOI : 10.7326/0003-4819-137-1-200207020-00014

S. Smith, I. Sestak, A. Forster, A. Partridge, L. Side et al., Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis, Annals of Oncology, vol.27, issue.4, pp.575-90, 2016.
DOI : 10.1093/annonc/mdv590

A. Mckay, W. Martin, and S. Latosinsky, How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide, Breast Cancer Research and Treatment, vol.216, issue.2, pp.153-162, 2005.
DOI : 10.3181/00379727-216-44176

A. Dillard, P. Ubel, D. Smith, B. Zikmund-fisher, V. Nair et al., The Distinct Role of Comparative Risk Perceptions in a Breast Cancer Prevention Program, Annals of Behavioral Medicine, vol.54, issue.2, pp.262-270, 2011.
DOI : 10.1037/0003-066X.54.2.93

D. Stacey, C. Degrasse, and L. Johnston, Addressing the Support Needs of Women at High Risk for Breast Cancer: Evidence-Based Care by Advanced Practice Nurses, Oncology Nursing Forum, vol.29, issue.6, pp.77-84, 2002.
DOI : 10.1188/02.ONF.E77-E84

D. Moher, A. Liberati, J. Tetzlaff, D. Altman, P. The et al., Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, PLoS Medicine, vol.6, issue.7, p.10000097, 2009.

V. Goldenberg, V. Seewaldt, V. Scott, G. Bean, G. Broadwater et al., Atypia in Random Periareolar Fine-Needle Aspiration Affects the Decision of Women at High Risk to Take Tamoxifen for Breast Cancer Chemoprevention, Cancer Epidemiology Biomarkers & Prevention, vol.16, issue.5, pp.1032-1036, 2007.
DOI : 10.1158/1055-9965.EPI-06-0910

C. Julian-reynier, J. Bouchard, D. Evans, F. Eisinger, W. Foulkes et al., Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another, Cancer, vol.15, issue.4, pp.959-68, 2001.
DOI : 10.1155/1999/140498

A. Muir, B. Meiser, M. Tucker, L. Andrews, K. Tucker et al., The Feasibility of Women at High Risk for Breast Cancer Participating in Chemoprevention Trials, Journal of Psychosocial Oncology, vol.352, issue.4, pp.31-45, 2004.
DOI : 10.1200/JCO.20.5.1260

T. Salant, P. Ganschow, O. Olopade, and D. Lauderdale, ???Why take it if you don???t have anything???? breast cancer risk perceptions and prevention choices at a public hospital, Journal of General Internal Medicine, vol.118, issue.7, pp.779-85, 2006.
DOI : 10.1002/ajmg.a.10150

M. Underhill, R. Lally, M. Kiviniemi, C. Murekeyisoni, and S. Dickerson, Living My Family???s Story, Cancer Nursing, vol.35, issue.6, pp.493-504, 2012.
DOI : 10.1097/NCC.0b013e31824530fa

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635541/pdf

A. Altschuler and C. Somkin, Women's Decision Making About Whether or Not to Use Breast Cancer Chemoprevention, Women & Health, vol.7, issue.2, pp.81-95, 2005.
DOI : 10.1007/BF02895155

S. Bober, L. Hoke, R. Duda, M. Regan, and N. Tung, Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors, Journal of Clinical Oncology, vol.22, issue.24, pp.4951-4958, 2004.
DOI : 10.1200/JCO.2004.05.192

C. Julian-reynier, J. Mancini, E. Mouret-fourme, M. Gauthier-villars, V. Bonadona et al., Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations, European Journal of Human Genetics, vol.91, issue.5, pp.500-506, 2011.
DOI : 10.1016/j.ejca.2006.09.009

URL : https://hal.archives-ouvertes.fr/hal-00697966

B. Meiser, P. Butow, M. Price, B. Bennett, G. Berry et al., Attitudes to Prophylactic Surgery and Chemoprevention in Australian Women at Increased Risk for Breast Cancer, Journal of Women's Health, vol.12, issue.8, pp.769-78, 2003.
DOI : 10.1089/154099903322447738

D. Paterniti, J. Melnikow, J. Nuovo, S. Henderson, M. Degregorio et al., I'm going to die of something anyway " : women's perceptions of tamoxifen for breast cancer risk reduction, Ethn Dis, vol.15, issue.3, pp.365-72, 2005.

M. Ropka, J. Keim, and J. Philbrick, Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis, Journal of Clinical Oncology, vol.28, issue.18, pp.3090-3095, 2010.
DOI : 10.1200/JCO.2009.27.8077

A. Fagerlin, A. Dillard, D. Smith, B. Zikmund-fisher, R. Pitsch et al., Women???s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid, Breast Cancer Research and Treatment, vol.18, issue.11, pp.681-689, 2011.
DOI : 10.1037/0022-3514.65.1.113

E. Matloff, A. Moyer, K. Shannon, K. Niendorf, and N. Col, Healthy Women with a Family History of Breast Cancer: Impact of a Tailored Genetic Counseling Intervention on Risk Perception, Knowledge, and Menopausal Therapy Decision Making, Journal of Women's Health, vol.15, issue.7, pp.843-56, 2006.
DOI : 10.1089/jwh.2006.15.843

R. Taylor and K. Taguchi, Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump, The Annals of Family Medicine, vol.3, issue.3, pp.242-249, 2005.
DOI : 10.1370/afm.284

A. Dillard, L. Scherer, P. A. Ubel, D. M. Smith, B. J. Zikmund-fisher et al., Breast cancer anxiety's associations with responses to a chemoprevention decision aid, Social Science & Medicine, vol.77, issue.0, pp.77-90, 2013.
DOI : 10.1016/j.socscimed.2012.10.009

S. Gorin, C. Wang, P. Raich, D. Bowen, and J. Hay, Decision making in cancer primary prevention and chemoprevention, Annals of Behavioral Medicine, vol.334, issue.5, pp.179-87, 2006.
DOI : 10.1093/jnci/dji306

J. Tjia, E. Micco, and K. Armstrong, Interest in breast cancer chemoprevention among older women, Breast Cancer Research and Treatment, vol.137, issue.1 Suppl, pp.435-53, 2008.
DOI : 10.7326/0003-4819-137-1-200207020-00014

A. Kinney, C. Richards, S. Vernon, and V. Vogel, The Effect of Physician Recommendation on Enrollment in the Breast Cancer Chemoprevention Trial, Preventive Medicine, vol.27, issue.5, pp.713-722, 1998.
DOI : 10.1006/pmed.1998.0349

A. Kinney, S. Vernon, R. Frankowski, D. Weber, J. Bitsura et al., Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment, Cancer, vol.12, issue.1, pp.46-56, 1995.
DOI : 10.1177/109019818801500203

A. Kinney, S. Vernon, W. Shui, D. Weber, M. Schell et al., Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer, Cancer Epidemiol Biomarkers Prev, vol.7, pp.591-596, 1998.

E. Port, L. Montgomery, A. Heerdt, and P. Borgen, Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention, Annals of Surgical Oncology, vol.281, issue.7, pp.580-585, 2001.
DOI : 10.1016/S0140-6736(98)85012-5

M. Cyrus-david and S. Strom, Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer, Psycho-Oncology, vol.88, issue.6, pp.521-554, 2001.
DOI : 10.1093/jnci/88.16.1100

C. Loehberg, J. S. Haeberle, L. Heusinger, K. Dilbat, G. Hein et al., Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial, Breast Cancer Research and Treatment, vol.101, issue.6, pp.101-111, 2010.
DOI : 10.7326/0003-4819-148-5-200803040-00004

URL : https://hal.archives-ouvertes.fr/hal-00519614

W. Mckinnon, S. Naud, T. Ashikaga, R. Colletti, and M. Wood, Results of an Intervention for Individuals and Families with BRCA Mutations: A Model for Providing Medical Updates and Psychosocial Support Following Genetic Testing, Journal of Genetic Counseling, vol.378, issue.12, pp.433-56, 2007.
DOI : 10.1097/00006842-197905000-00004

G. Rondanina, M. Puntoni, G. Severi, C. Varricchio, A. Zunino et al., Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users, Journal of Clinical Oncology, vol.26, issue.9, pp.1537-1580, 2008.
DOI : 10.1200/JCO.2007.13.6739

J. Tchou, N. Hou, A. Rademaker, V. Jordan, and M. Morrow, Acceptance of tamoxifen chemoprevention by physicians and women at risk, Cancer, vol.137, issue.9, pp.1800-1806, 2004.
DOI : 10.7326/0003-4819-137-1-200207020-00017

S. Domchek, T. F. Singer, C. Evans, D. Lynch, H. Isaacs et al., Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality, JAMA, vol.304, issue.9, pp.967-75, 2010.
DOI : 10.1001/jama.2010.1237

A. Maisonneuve, L. Huiart, L. Rabayrol, D. Horsman, R. Didelot et al., Acceptability of cancer chemoprevention trials: impact of the design, International Journal of Medical Sciences
DOI : 10.7150/ijms.5.244

B. Meiser, P. Butow, M. Friedlander, V. Schnieden, M. Gattas et al., Intention to Undergo Prophylactic Bilateral Mastectomy in Women at Increased Risk of Developing Hereditary Breast Cancer, Journal of Clinical Oncology, vol.18, issue.11, pp.2250-2257, 2000.
DOI : 10.1200/JCO.2000.18.11.2250

H. Leventhal and . In, Emotional and behavioural responses, in Stress and medical procedures, Oxford: Oxford Science, pp.25-57, 1989.

H. Gooding, K. Organista, J. Burack, B. Biesecker, and B. , Genetic susceptibility testing from a stress and coping perspective, Social Science & Medicine, vol.62, issue.8, pp.1880-90, 2006.
DOI : 10.1016/j.socscimed.2005.08.041

T. Marteau and J. Weinmann, Self-regulation and the behavioural response to DNA risk information: A theoretical analysis and framework for future research, Social Science & Medicine, vol.62, issue.6, pp.1360-1368, 2006.
DOI : 10.1016/j.socscimed.2005.08.005

C. Jones, H. Smith, and C. Llewellyn, Evaluating the effectiveness of health belief model interventions in improving adherence: a systematic review, Health Psychology Review, vol.26, issue.3, pp.253-69, 2014.
DOI : 10.1037/0278-6133.22.1.99

J. Gronwald, A. Robidoux, C. Kim-sing, N. Tung, H. Lynch et al., Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, Breast Cancer Research and Treatment, vol.22, issue.2, pp.421-428, 2014.
DOI : 10.1093/annonc/mdq427

I. Collins, A. Bickerstaffe, T. Ranaweera, S. Maddumarachchi, L. Keogh et al., iPrevent??: a tailored, web-based, decision support tool for breast cancer risk assessment and management, Breast Cancer Research and Treatment, vol.21, issue.7, pp.171-82, 2016.
DOI : 10.5694/mja13.10848

J. Cuzick, I. Sestak, S. Cawthorn, H. Hamed, A. Holli et al., Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial, The Lancet Oncology, vol.16, issue.1, pp.67-75, 2015.
DOI : 10.1016/S1470-2045(14)71171-4